Dr. Sepp Jansen
Experimental Pharmacology
European Center for Angioscience (ECAS)
Medical Faculty Mannheim, Heidelberg University
Professional Career
Since 2016
Postdoctoral Fellow
Institute for Experimental and Clinical Pharmacology and Toxicology
Medical Faculty Mannheim, Heidelberg University, Germany
2016
Ph.D.
University of Groningen, The Netherlands
Selected Publications
Jansen SR, Gosens R, Wieland T, Schmidt M: Paving the Rho in cancer metastasis: Rho GTPases and beyond. Pharmacol Ther, 183:1-21, 2018.
Garg J, Feng YX, Jansen SR, Friedrich J, Lezoualc'h F, Schmidt M, Wieland T: Catecholamines facilitate VEGF-dependent angiogenesis via β2-adrenoceptor-induced Epac1 and PKA activation. Oncotarget, 8:44732-48, 2017.
Jansen SR, Poppinga WJ, de Jager W, Lezoualc'h F, Cheng X, Wieland T, Yarwood SJ, Gosens R, Schmidt M: Epac1 links prostaglandin E2 to β-catenin-dependent transcription during epithelial-to-mesenchymal transition. Oncotarget, 7:46354-70, 2016.
Spanjer AR, Baarsma HA, Oostenbrin LM, Jansen SR, Kuipers CC, Lindner M, Postma DS, Meurs H, Heijink IH, Gosens R, Königshoff M: TGFβ-induced profibrotic signaling is regulated in part by the WNT receptor Frizzled-8. FASEB J, 30:1823-35, 2016.
Jansen SR, Holman R, Hedemann I, Frankes E, Elzinga CR, Timens W, Gosens R, de Bont ES, Schmidt M: Prostaglandin E2 promotes MYCN non-amplified neuroblastoma cell survival via β-catenin stabilization. J Cell Mol Med, 19:210-26, 2015.
Jansen SR, Van Ziel AM, Baarsma HA, Gosens R: β-Catenin regulates airway smooth muscle contraction. Am J Physiol Lung Cell Mol Physiol, 299:204-14, 2010.